62 results
Page 3 of 4
8-K
EX-99.1
s4cwmn8v1gyw2fj176
5 Nov 19
Top-line data from PROTECTOR 1 study expected by early first quarter of 2020
8:00am
8-K
EX-99.1
z624y5
14 Aug 19
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
h7vr2hfp9cgc0 q2
23 Jul 19
Other Events
8:05am
8-K
EX-99.1
4yxng8
15 May 19
Results of Operations and Financial Condition
9:00am
8-K
EX-99.2
szrzi51 6kom6wsme
15 May 19
Results of Operations and Financial Condition
9:00am
8-K
EX-99.1
y4ns cn92y9z710uo
9 May 19
Other Events
8:10am
8-K
EX-99.1
h4496 q57e6y
20 Mar 19
Public Offering of Common Stock
9:42pm
424B5
56t3izomi
20 Mar 19
Prospectus supplement for primary offering
5:13pm
424B5
v9os hzr83m33malva
18 Mar 19
Prospectus supplement for primary offering
4:25pm
8-K
EX-99.1
lzmpez3g
18 Mar 19
Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19
4:02pm
8-K
EX-99.2
gmftl ufxhm
18 Mar 19
Regulation FD Disclosure
7:21am
S-3
s4dhn73ze9u8
1 Feb 19
Shelf registration
5:31pm
8-K
EX-99.1
3k7g4uy
13 Nov 18
Initiation of pivotal Phase 3 program of RTB101 in RTIs expected in 1H19
8:10am
8-K
EX-99.1
3qmefwmei4
6 Nov 18
Departure of Directors or Certain Officers
8:08am
8-K
EX-99.2
54hu2e0noxe61kw21yh
16 Oct 18
Regulation FD Disclosure
7:20am
8-K
EX-99.1
mp3arep38s7ggnk
15 Aug 18
Departure of Directors or Certain Officers
8:15am
8-K
EX-99.1
44g037uzkeqh5
9 Aug 18
Results of Operations and Financial Condition
8:15am